Opiant Pharmaceuticals, Inc.

NasdaqCM:OPNT Stock Report

Market Cap: US$108.8m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

Opiant Pharmaceuticals Valuation

Is OPNT undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

3/6

Valuation Score 3/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Sales vs Peers

  • Price-To-Sales vs Industry

  • Price-To-Sales vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of OPNT when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: OPNT ($20.65) is trading below our estimate of fair value ($250.88)

Significantly Below Fair Value: OPNT is trading below fair value by more than 20%.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for OPNT?

Key metric: As OPNT is unprofitable we use its Price-To-Sales Ratio for relative valuation analysis.

The above table shows the Price to Sales ratio for OPNT. This is calculated by dividing OPNT's market cap by their current revenue.
What is OPNT's PS Ratio?
PS Ratio4.9x
SalesUS$22.34m
Market CapUS$108.80m

Price to Sales Ratio vs Peers

How does OPNT's PS Ratio compare to its peers?

The above table shows the PS ratio for OPNT vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PSEstimated GrowthMarket Cap
Peer Average1.3x
AMLX Amylyx Pharmaceuticals
1.9x-68.6%US$385.3m
UPC Universe Pharmaceuticals
0.1xn/aUS$2.9m
BSEM BioStem Technologies
1.1x20.1%US$223.5m
DERM Journey Medical
2x24.0%US$119.9m
OPNT Opiant Pharmaceuticals
4.9x39.5%US$108.8m

Price-To-Sales vs Peers: OPNT is good value based on its Price-To-Sales Ratio (4.9x) compared to the peer average (9.4x).

Price to Sales Ratio vs Industry

How does OPNT's PS Ratio compare vs other companies in the US Pharmaceuticals Industry?

70 CompaniesPrice / SalesEstimated GrowthMarket Cap
OGN Organon
0.6x-0.06%US$4.16b
PRGO Perrigo
0.9x3.4%US$3.87b
BHC Bausch Health Companies
0.3x1.5%US$2.92b
AMRX Amneal Pharmaceuticals
1x5.6%US$2.60b
OPNT 4.9xIndustry Avg. 2.9xNo. of Companies70PS048121620+
70 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Sales vs Industry: OPNT is expensive based on its Price-To-Sales Ratio (4.9x) compared to the US Pharmaceuticals industry average (2.9x).

Price to Sales Ratio vs Fair Ratio

What is OPNT's PS Ratio compared to its Fair PS Ratio? This is the expected PS Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

OPNT PS Ratio vs Fair Ratio.
Fair Ratio
Current PS Ratio4.9x
Fair PS Ratio3.2x

Price-To-Sales vs Fair Ratio: OPNT is expensive based on its Price-To-Sales Ratio (4.9x) compared to the estimated Fair Price-To-Sales Ratio (3.2x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst OPNT forecast and predictions for the stock price in 12 month’s time.
DateShare PriceAverage 1Y Price TargetDispersionHighLow1Y Actual priceAnalysts
Currentn/a
US$21.50
0%
2.3%US$22.00US$21.00n/a2
Nov ’25n/a
US$21.50
0%
2.3%US$22.00US$21.00n/a2
Oct ’25n/a
US$21.50
0%
2.3%US$22.00US$21.00n/a2
Sep ’25n/a
US$21.50
0%
2.3%US$22.00US$21.00n/a2
Aug ’25n/a
US$21.50
0%
2.3%US$22.00US$21.00n/a2
Jul ’25n/a
US$21.50
0%
2.3%US$22.00US$21.00n/a2
Jun ’25n/a
US$21.50
0%
2.3%US$22.00US$21.00n/a2
May ’25n/a
US$21.50
0%
2.3%US$22.00US$21.00n/a2
Apr ’25n/a
US$21.50
0%
2.3%US$22.00US$21.00n/a2
Mar ’25n/a
US$21.50
0%
2.3%US$22.00US$21.00n/a2
Feb ’25n/a
US$21.50
0%
2.3%US$22.00US$21.00n/a2
Jan ’25n/a
US$21.50
0%
2.3%US$22.00US$21.00n/a2
Dec ’24n/a
US$21.50
0%
2.3%US$22.00US$21.00n/a2
Nov ’24n/a
US$21.50
0%
2.3%US$22.00US$21.00n/a2
Oct ’24n/a
US$21.50
0%
2.3%US$22.00US$21.00n/a2
Sep ’24n/a
US$21.50
0%
2.3%US$22.00US$21.00n/a2
Aug ’24n/a
US$21.50
0%
2.3%US$22.00US$21.00n/a2
Jul ’24n/a
US$21.50
0%
2.3%US$22.00US$21.00n/a2
Jun ’24n/a
US$21.50
0%
2.3%US$22.00US$21.00n/a2
May ’24n/a
US$21.50
0%
2.3%US$22.00US$21.00n/a2
Apr ’24n/a
US$21.50
0%
2.3%US$22.00US$21.00n/a2
Mar ’24US$20.65
US$21.50
+4.1%
2.3%US$22.00US$21.00n/a2
Feb ’24US$20.03
US$21.50
+7.3%
2.3%US$22.00US$21.00n/a2
Jan ’24US$20.28
US$21.50
+6.0%
2.3%US$22.00US$21.00n/a2
Dec ’23US$20.19
US$21.50
+6.5%
2.3%US$22.00US$21.00n/a2
Nov ’23US$9.90
US$40.25
+306.6%
3.7%US$42.00US$38.00n/a4

Analyst Forecast: Target price is less than 20% higher than the current share price.

Discover undervalued companies

ANI Pharmaceuticals

US$1.1b

A biopharmaceutical company, develops, manufactures, and markets branded and generic prescription pharmaceuticals in the United States and Canada.

ANIP

US$57.86

7D

3.9%

1Y

15.0%

Teva Pharmaceutical Industries

US$18.9b

Develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally.

TEVA

US$16.59

7D

-1.3%

1Y

69.3%

Collegium Pharmaceutical

US$993.0m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$31.19

7D

4.8%

1Y

22.3%